Grade @-@ adverse events seen with a greater than @ % frequency with tecemotide were dyspnoea ( @ -LSB- @ % -RSB- of @ patients in the tecemotide group vs @ -LSB- @ % -RSB- of @ patients in the placebo group ) , metastases to central nervous system ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , and pneumonia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) .